VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+35.87%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$211M
AUM Growth
-$31.9M
(-13%)
Cap. Flow
-$85.7M
Cap. Flow
% of AUM
-40.6%
Top 10 Holdings %
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57
Top Buys
| 1 |
Delek Logistics
DKL
|
$1.51M |
| 2 |
Western Midstream Partners
WES
|
$1.18M |
| 3 |
Viper Energy
VNOM
|
$953K |
| 4 |
Marathon Petroleum
MPC
|
$839K |
| 5 |
EPR Properties
EPR
|
$814K |
Top Sells
| 1 |
Barings BDC
BBDC
|
$2.75M |
| 2 |
Prospect Capital
PSEC
|
$2.59M |
| 3 |
WhiteHorse Finance
WHF
|
$2.34M |
| 4 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$2.34M |
| 5 |
Nuveen Credit Strategies Income Fund
JQC
|
$2.27M |
Sector Composition
| 1 | Healthcare | 33.94% |
| 2 | Real Estate | 15.9% |
| 3 | Energy | 15.5% |
| 4 | Materials | 8.79% |
| 5 | Financials | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Arvinas
ARVN
$575M
| $374K | 0.18% |
11,162
+2,700
| +32% | +$90.5K |
|
227
FibroGen
FGEN
$48.9M
| $372K | 0.18% |
367
+59
| +19% | +$59.8K |
|
228
Madrigal Pharmaceuticals
MDGL
$9.65B
| $372K | 0.18% |
3,287
-396
| -11% | -$44.8K |
|
229
Oaktree Specialty Lending
OCSL
$1.23B
| $372K | 0.18% |
27,769
-114,452
| -80% | -$1.53M |
|
|
MRNS
230
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $372K | 0.18% |
+36,640
| New | +$372K |
|
|
ALLK
231
DELISTED
Allakos
ALLK
| $371K | 0.18% |
5,159
+2,231
| +76% | +$160K |
|
232
Ascendis Pharma
ASND
$12.5B
| $371K | 0.18% |
2,511
-606
| -19% | -$89.5K |
|
|
EFR
233
Eaton Vance Senior Floating-Rate Fund
EFR
$343M
| $371K | 0.18% |
32,798
-149,534
| -82% | -$1.69M |
|
234
Gossamer Bio
GOSS
$668M
| $371K | 0.18% |
28,554
+14,388
| +102% | +$187K |
|
235
Cartesian Therapeutics
RNAC
$277M
| $371K | 0.18% |
+4,357
| New | +$371K |
|
236
Allogene Therapeutics
ALLO
$255M
| $370K | 0.18% |
8,650
-4,629
| -35% | -$198K |
|
237
Zymeworks
ZYME
$1.14B
| $370K | 0.18% |
10,248
+1,691
| +20% | +$61.1K |
|
|
TPTX
238
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $370K | 0.18% |
5,728
-770
| -12% | -$49.7K |
|
239
Apellis Pharmaceuticals
APLS
$3.55B
| $369K | 0.17% |
11,299
-1,697
| -13% | -$55.4K |
|
240
Alaunos Therapeutics
TCRT
$4.27M
| $369K | 0.17% |
751
+265
| +55% | +$130K |
|
241
Ardelyx
ARDX
$1.57B
| $368K | 0.17% |
53,159
+1,800
| +4% | +$12.5K |
|
242
CytomX Therapeutics
CTMX
$376M
| $367K | 0.17% |
44,006
-6,220
| -12% | -$51.9K |
|
243
Regenxbio
RGNX
$490M
| $367K | 0.17% |
9,952
+1,716
| +21% | +$63.3K |
|
|
IMGN
244
DELISTED
Immunogen Inc
IMGN
| $367K | 0.17% |
79,795
-20,636
| -21% | -$94.9K |
|
245
Gladstone Investment Corp
GAIN
$543M
| $366K | 0.17% |
35,790
-145,344
| -80% | -$1.49M |
|
246
Xenon Pharmaceuticals
XENE
$3.02B
| $366K | 0.17% |
+29,170
| New | +$366K |
|
|
EIDX
247
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $366K | 0.17% |
7,669
+2,002
| +35% | +$95.5K |
|
248
Voyager Therapeutics
VYGR
$235M
| $364K | 0.17% |
28,874
+2,166
| +8% | +$27.3K |
|
249
Moderna
MRNA
$9.78B
| $363K | 0.17% |
5,660
-13,644
| -71% | -$875K |
|
|
CALA
250
DELISTED
Calithera Biosciences, Inc
CALA
| $362K | 0.17% |
+3,427
| New | +$362K |
|